Genetic Microdevices Ltd

genetic-microdevices.co.uk

Genetic Microdevices Ltd has developed a disruptive technology that analyses proteins and DNA with ultra-high performance. The instrument is based on a disposable analysis chip. Protein and DNA analysis are central to any biological analysis including drug development, research and diagnostics. Our device encompasses unique intellectual property which makes it far more potent than directly competing analytical devices. A key feature of the technology is that it performs the advanced analysis using a disposable microfluidic cartridge that can separate biological molecules with unprecedented sensitivity and resolution.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

CO-DIAGNOSTICS, INC. TO ANNOUNCE EXPANSION OF OEM AGREEMENT WITH BIO MOLECULAR SYSTEMS AT AACC

Co-Diagnostics | July 27, 2022

news image

Co-Diagnostics, Inc. a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing ...

Read More

BICYCLE AND GENENTECH FORGE IMMUNO-ONCOLOGY COLLABORATION WORTH UP TO $1.7 BILLION

BioSpace | February 25, 2020

news image

Shares of U.K.-based Bicycle Therapeutics are climbing this morning after the company announced it entered into a strategic immuno-oncology collaboration with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. The collaboration has a value of up to $1.7 billion if all milestones are hit. Under terms of the agreement, Bicycle will receive an upfront payment of $30 million to focus its proprietary bicyclic peptides platform on a wide range of immuno-onc...

Read More

MOLECULIN ANNOUNCES DISCOVERY OF SIGNIFICANT IN VITRO ACTIVITY AGAINST SARS-COV-2

Moleculin | September 29, 2020

news image

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repea...

Read More

Medical

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

news image

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More
news image

Industrial Impact

CO-DIAGNOSTICS, INC. TO ANNOUNCE EXPANSION OF OEM AGREEMENT WITH BIO MOLECULAR SYSTEMS AT AACC

Co-Diagnostics | July 27, 2022

Co-Diagnostics, Inc. a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing ...

Read More
news image

BICYCLE AND GENENTECH FORGE IMMUNO-ONCOLOGY COLLABORATION WORTH UP TO $1.7 BILLION

BioSpace | February 25, 2020

Shares of U.K.-based Bicycle Therapeutics are climbing this morning after the company announced it entered into a strategic immuno-oncology collaboration with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. The collaboration has a value of up to $1.7 billion if all milestones are hit. Under terms of the agreement, Bicycle will receive an upfront payment of $30 million to focus its proprietary bicyclic peptides platform on a wide range of immuno-onc...

Read More
news image

MOLECULIN ANNOUNCES DISCOVERY OF SIGNIFICANT IN VITRO ACTIVITY AGAINST SARS-COV-2

Moleculin | September 29, 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repea...

Read More
news image

Medical

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us